Efficacy of ertugliflozin (ERTU) on hospitalisation for heart failure (HHF) across the spectrum of pre-trial ejection fraction (EF): post hoc analyses of VERTIS CV
In this medfyle
There is controversy over whether SGLT2 inhibitors have efficacy in high-risk patients with HF and EF >60%. This Phase 3 VERTIS CV trial found that, in patients with T2D and ASCVD, the efficacy of ertugliflozin in preventing the first HHF was generally comparable across the spectrum of pre-trial EF and the trend for greater benefit at lower EF was statistically significant for total HHF.
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
About this Medfyle
This is a highlights summary of an oral session given at the EASD Annual Meeting 2022 and presented by:
Dr. Ambarish Pandey
UT Southwestern Medical Center
Dallas, TX, USA
The content is produced by Infomedica. The presenting authors of the original session had no part in the creation of this conference highlights summary.
